BR9713400A - Processes and compounds to inhibit beta-amyloid peptide release and / or its synthesis. - Google Patents

Processes and compounds to inhibit beta-amyloid peptide release and / or its synthesis.

Info

Publication number
BR9713400A
BR9713400A BR9713400-7A BR9713400A BR9713400A BR 9713400 A BR9713400 A BR 9713400A BR 9713400 A BR9713400 A BR 9713400A BR 9713400 A BR9713400 A BR 9713400A
Authority
BR
Brazil
Prior art keywords
synthesis
amyloid peptide
compounds
processes
release
Prior art date
Application number
BR9713400-7A
Other languages
Portuguese (pt)
Inventor
James E Audia
Thomas C Britton
James J Droste
Beverly K Folmer
George W Huffman
Varghese John
Lee H Latimer
Thomas E Mabry
Jeffrey S Nissen
Warren J Porter
Jon K Reel
Eugene D Thorsett
Jay S Tung
Jing Wu
Clark Norman Eid
William Leonard Scott
Original Assignee
Elan Pharm Inc
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, Lilly Co Eli filed Critical Elan Pharm Inc
Publication of BR9713400A publication Critical patent/BR9713400A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção:<B>"PROCESSOS E COMPOSTOS PARA INIBIR LIBERAçãO DE PEPTìDEO BETA-AMILóIDE E/OU SUA SìNTESE"<D>. São revelados compostos que inibem a liberação de peptídeo <225>-amilóide e/ou síntese e, consequentemente, possui utilidade no tratamento da doença de Alzheimer. Também são reveladas composições farmacêuticas compreendendo um composto que inibe a liberação de peptídeo <225>-amilóide e/ou sua síntese, bem como processos para tratamento da doença de Alzherimer ambas, profilática e terapeuticamente com tais composições farmacêuticas.Invention Patent: <B> "PROCESSES AND COMPOUNDS TO INHIBIT BETA-AMYLOID PEPTIDE RELEASE AND / OR ITS SYNTHESIS" <D>. Compounds are disclosed that inhibit the release of <225> -amyloid peptide and / or synthesis and, consequently, have utility in the treatment of Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound that inhibits the release of β-amyloid peptide and / or its synthesis, as well as processes for treating Alzherimer disease both prophylactically and therapeutically with such pharmaceutical compositions.

BR9713400-7A 1996-11-22 1997-11-21 Processes and compounds to inhibit beta-amyloid peptide release and / or its synthesis. BR9713400A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75544296A 1996-11-22 1996-11-22
US80752897A 1997-02-28 1997-02-28
US80742797A 1997-02-28 1997-02-28
US80852897A 1997-02-28 1997-02-28
PCT/US1997/020804 WO1998022494A2 (en) 1996-11-22 1997-11-21 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS

Publications (1)

Publication Number Publication Date
BR9713400A true BR9713400A (en) 2000-01-25

Family

ID=27505670

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713400-7A BR9713400A (en) 1996-11-22 1997-11-21 Processes and compounds to inhibit beta-amyloid peptide release and / or its synthesis.

Country Status (21)

Country Link
EP (1) EP0942924A2 (en)
JP (1) JP2001503782A (en)
KR (1) KR20000069064A (en)
CN (1) CN1238779A (en)
AR (1) AR016751A1 (en)
AU (1) AU5356198A (en)
BR (1) BR9713400A (en)
CA (1) CA2267634A1 (en)
CO (1) CO4910156A1 (en)
CZ (1) CZ122899A3 (en)
EA (1) EA199900490A1 (en)
HR (1) HRP970627A2 (en)
HU (1) HUP0100270A3 (en)
ID (1) ID22044A (en)
IL (1) IL129083A0 (en)
NO (1) NO992368L (en)
NZ (1) NZ334690A (en)
PE (1) PE16999A1 (en)
TR (3) TR199902937T2 (en)
WO (1) WO1998022494A2 (en)
YU (1) YU46097A (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000020I1 (en) 1996-04-25 2010-07-08 Prosidion Ltd Method for lowering the blood glucose level in mammals
US6191166B1 (en) * 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
DE19823831A1 (en) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim New pharmaceutical use of isoleucyl thiazolidide and its salts
CA2325389A1 (en) * 1998-06-22 1999-12-29 James E. Audia Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
CA2324475A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
WO1999067219A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
DE19828114A1 (en) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs of unstable inhibitors of dipeptidyl peptidase IV
DE19828113A1 (en) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs of Dipeptidyl Peptidase IV Inhibitors
DE19834591A1 (en) 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Use of substances that decrease the activity of dipeptidyl peptidase IV to increase blood sugar levels, e.g. for treating hypoglycemia
JP2003524601A (en) * 1998-09-30 2003-08-19 エラン ファーマシューティカルズ，インコーポレイテッド Biological reagents and methods for determining the mechanism of β-amyloid peptide production
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
EP1137661A1 (en) 1998-12-10 2001-10-04 F. Hoffmann-La Roche Ag Procollagen c-proteinase inhibitors
SI20876B (en) * 1999-05-07 2009-08-31 Texas Biotechnology Corp Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
DE19926233C1 (en) 1999-06-10 2000-10-19 Probiodrug Ges Fuer Arzneim Production of thiazolidine, useful as pharmaceutical intermediate, comprises reacting hexamethylenetetramine with cysteamine
DE19940130A1 (en) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim New effectors of Dipeptidyl Peptidase IV for topical use
CA2388750A1 (en) * 1999-11-09 2001-05-17 James Edmund Audia .beta.-aminoacid compounds useful for inhibiting .beta.-amyloid peptide release and/or its synthesis
HU229042B1 (en) 2000-03-31 2013-07-29 Prosidion Ltd Method for the improvement of islet signaling in diabetes mellitus and for its prevention
AU2001261728A1 (en) 2000-05-17 2001-11-26 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
AU783857B2 (en) 2000-06-01 2005-12-15 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of a beta protein production
FR2832152A1 (en) * 2001-11-09 2003-05-16 Aventis Pharma Sa New 2-amino-thiazoline derivatives having inducible NO-synthase inhibiting activity, useful for treating Parkinson's, cerebral disorders, migraines, depression, diabetes
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
GB0016681D0 (en) 2000-07-06 2000-08-23 Merck Sharp & Dohme Therapeutic compounds
US7132104B1 (en) 2000-10-27 2006-11-07 Probiodrug Ag Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
US6890905B2 (en) 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
DE10150203A1 (en) 2001-10-12 2003-04-17 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitor in treatment of cancer
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
FR2840899B1 (en) * 2002-06-12 2005-02-25 Sanofi Synthelabo ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS
AR039059A1 (en) * 2001-08-06 2005-02-09 Sanofi Aventis COMPOUND DERIVED FROM ACILAMINOTIAZOL, ITS USE, PROCEDURES TO PREPARE IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, AND INTERMEDIARY COMPOUNDS
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
DE10143840A1 (en) * 2001-09-06 2003-03-27 Probiodrug Ag New acylated hydroxamates useful for the treatment of e.g. wound healing
CN1314674C (en) 2001-11-09 2007-05-09 安万特医药股份有限公司 Use of 2-amino-thiazoline derivatives as inhibitors of inducible NO-synthase
HUP0600057A2 (en) 2002-02-28 2006-05-29 Prosidion Ltd Glutaminyl based dpiv inhibitors, pharmaceutical compositions comprising thereof and their use
KR101076018B1 (en) * 2003-01-08 2011-10-21 유니버시티 오브 워싱톤 Antibacterial agents
ATE462432T1 (en) 2003-05-05 2010-04-15 Probiodrug Ag GLUTAMINYL CYCLASE INHIBITORS
US7381537B2 (en) 2003-05-05 2008-06-03 Probiodrug Ag Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease
EP1666068A4 (en) * 2003-09-24 2010-08-04 Santen Pharmaceutical Co Ltd Remedy for eye diseases accompanied by optic nerve injuries
KR20120007079A (en) 2003-10-15 2012-01-19 프로비오드룩 아게 Use of effectors of glutaminyl and glutamate cyclases
CN107021895A (en) 2007-06-12 2017-08-08 尔察祯有限公司 Antiseptic
EP2062909A1 (en) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
BG110141A (en) 2008-05-23 2009-12-31 "Софарма" Ад Galanthamine derivatives, methods for their obtaining and use
EP2847168A1 (en) 2012-05-10 2015-03-18 Achaogen, Inc. Antibacterial agents
WO2017004560A1 (en) * 2015-07-02 2017-01-05 The Regents Of The University Of California Methods and compositions for amyloid aggregates
US20240010642A1 (en) * 2021-01-05 2024-01-11 Southern Research Institute Modulators of programmed death-ligand-1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661270B2 (en) * 1990-03-05 1995-07-20 Cephalon, Inc. Chymotrypsin-like proteases and their inhibitors
WO1995013084A1 (en) * 1992-05-11 1995-05-18 Miles Inc. Cathepsin d is an amyloidogenic protease in alzheimer's disease
NZ264143A (en) * 1993-08-09 1996-11-26 Lilly Co Eli Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production
CA2171882C (en) * 1993-10-01 2001-12-04 Barbara Cordell Inhibitors of .beta.-amyloid protein production
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5872101A (en) * 1995-01-06 1999-02-16 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
JPH11506923A (en) * 1995-06-06 1999-06-22 アセナ ニューロサイエンシーズ，インコーポレイテッド New cathepsins and methods and compositions for their inhibition

Also Published As

Publication number Publication date
NO992368D0 (en) 1999-05-14
JP2001503782A (en) 2001-03-21
NO992368L (en) 1999-06-21
KR20000069064A (en) 2000-11-25
CO4910156A1 (en) 2000-04-24
WO1998022494A3 (en) 1998-11-26
AR016751A1 (en) 2001-08-01
CN1238779A (en) 1999-12-15
HUP0100270A2 (en) 2001-08-28
YU46097A (en) 2000-10-30
AU5356198A (en) 1998-06-10
HRP970627A2 (en) 1998-08-31
NZ334690A (en) 2001-09-28
WO1998022494A2 (en) 1998-05-28
TR199901133T2 (en) 1999-07-21
EA199900490A1 (en) 2000-02-28
TR199902938T2 (en) 2002-06-21
PE16999A1 (en) 1999-02-19
IL129083A0 (en) 2000-02-17
ID22044A (en) 1999-08-26
HUP0100270A3 (en) 2001-09-28
CZ122899A3 (en) 1999-10-13
TR199902937T2 (en) 2001-01-22
CA2267634A1 (en) 1998-05-28
EP0942924A2 (en) 1999-09-22

Similar Documents

Publication Publication Date Title
BR9713400A (en) Processes and compounds to inhibit beta-amyloid peptide release and / or its synthesis.
BR9714517A (en) Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising them and processes to inhibit beta-amyloid peptide release and / or its synthesis by using such compounds
BR9713404A (en) esters of n- (aryl / heteroarylacetyl) amino acids, pharmaceutical compositions comprising them, and methods for inhibiting the release of beta-amyloid peptide and / or its synthesis by using such compounds.
BR9807876A (en) Heterocyclic compounds and their use for inhibition of beta-amyloid peptide
BR9714358A (en) Derivatives of n- (aryl / heteroaryl) amino acid, pharmaceutical compositions comprising them, and methods for inhibiting the release of beta-amyloid peptide and / or its synthesis by using such compounds
BR0008922A (en) Compounds useful as anti-inflammatory agents
GB0129260D0 (en) Pharmaceutical compositions and their uses
ES2170104T3 (en) INHIBITORS OF THE PRODUCTION OF BETA-AMILOID PROTEINS.
BG101118A (en) Therapeutical compounds
ATE389724T1 (en) HUMAN DNASE I HYPERACTIVE VARIANTS
BR0115427A (en) Compound, pharmaceutical composition, methods for inhibiting the release of beta-amyloid peptide and / or its synthesis, for treating Alzheimer&#39;s disease, and for preventing the disease and the progress of Alzheimer&#39;s disease, and, use of a compound.
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
BR9913072A (en) Azacyclic ring systems, pharmaceutical composition, and process to induce analgesia
WO1998022441A3 (en) N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions, and methods for inhibiting beta-amyloid peptide and/or its synthesis
BG104179A (en) Phanquinon administration for the treatment of the alzheimer&#39;s disease
IL113940A (en) Synthetic peptides which are elastase inhibitors and pharmaceutical compositions for the treatment of neutrophil associated inflammatory disease containing said inhibitors
HUP0100611A2 (en) Triazine compounds for treatment of cns disorders
AU4568400A (en) Sphingomyelinase inhibitor
ATE230027T1 (en) HUMAN DNASE I VARIANTS
FI961505A0 (en) Novel Peptide Compounds Therapeutically Active in a Blood Coagulation System, Method for Their Preparation and Pharmaceutical Compositions Containing Them
ECSP972320A (en) METHODS AND COMPOSITIONS FOR INHIBITING THE RELEASE OF β-AMYLOID PEPTIDE AND / OR ITS SYNTHESIS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1894 DE 24/04/2007.